Loading stock data...

Concord Drugs Limited

BSE: CONCORD

BSE
84.55 -0.45 (-0.53%)

Prev Close

85

Open Price

84.58

Volume

2,882

Today Low / High

83.05 / 87.98

52 WK Low / High

26.1 / 92.52

Range

80 - 89

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 84.55, reflecting a change of -0.45 (-0.52941%). The expected target range on the BSE is 80 - 89. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.

05 Jan 84.58 -0.04%
02 Jan 82.99 2.42%
01 Jan 82.50 -1.72%
31 Dec 84.25 -2.10%
30 Dec 80.32 7.03%
29 Dec 84.99 -2.21%
26 Dec 84.00 1.14%
24 Dec 86.90 -2.90%
23 Dec 87.79 -5.50%
22 Dec 81.96 2.07%
19 Dec 84.40 -0.91%
18 Dec 78.65 4.67%
17 Dec 86.90 -5.64%
16 Dec 88.50 -3.40%
15 Dec 87.50 0.49%
12 Dec 85.08 -0.05%
11 Dec 76.51 5.91%
10 Dec 74.94 2.99%
09 Dec 74.79 -1.71%
08 Dec 76.95 -3.68%

Concord Drugs Limited Graph

Concord Drugs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Concord Drugs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 84.55, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 84.55 85.40 76.86 - 93.94
86.24 68.99 - 103.49
87.09 60.96 - 113.21
Bearish Scenario 84.55 83.70 75.33 - 92.07
82.86 66.29 - 99.43
82.01 57.41 - 106.62

Overview of Concord Drugs Limited

ISIN

INE858L01010

Industry

Medical - Pharmaceuticals

Vol.Avg

10,178

Market Cap

841,276,136

Last Dividend

0

Official Website

Visit Website

IPO Date

2015-02-23

DCF Diff

110.23

DCF

-27

Financial Ratios Every Investor Needs

Stock Rating Details for CONCORD

Metric Value Recommendation
Overall Rating C+ Sell
DCF Score 1 Strong Sell
ROE Score 2 Sell
ROA Score 3 Neutral
Debt-to-Equity (DE) Score 2 Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 3 Neutral

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2025-03-31 45.24 Cr 35.23 Cr 10.01 Cr 0.2213 0.00 Cr 0.00 Cr 2.70 Cr 0.34 Cr 0.34 4.15 Cr 0.0074
2024-03-31 44.92 Cr 33.25 Cr 11.67 Cr 0.2598 0.00 Cr 0.17 Cr 2.54 Cr 0.47 Cr 0.47 4.05 Cr 0.0105
2023-03-31 52.08 Cr 41.03 Cr 11.05 Cr 0.2122 0.00 Cr 0.21 Cr 3.04 Cr 0.99 Cr 1.06 4.58 Cr 0.0189
2022-03-31 58.96 Cr 42.14 Cr 16.82 Cr 0.2853 0.00 Cr 0.23 Cr 9.16 Cr 1.59 Cr 1.82 5.69 Cr 0.0270
2021-03-31 51.36 Cr 43.07 Cr 8.29 Cr 0.1613 0.00 Cr 0.23 Cr 2.00 Cr 3.28 Cr 3.75 6.99 Cr 0.0639

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2025-03-31 0.12 Cr 65.14 Cr 31.03 Cr 34.1136 Cr 17.19 Cr 17.07 Cr 25.27 Cr 13.57 Cr 0.00 Cr 0.00 Cr 0.80 Cr 26.1802 Cr
2024-03-31 0.15 Cr 58.81 Cr 24.99 Cr 33.8178 Cr 17.52 Cr 17.37 Cr 22.92 Cr 12.67 Cr 0.00 Cr 0.00 Cr 0.84 Cr 21.3410 Cr
2023-03-31 0.08 Cr 58.23 Cr 26.53 Cr 31.7044 Cr 16.96 Cr 16.89 Cr 20.06 Cr 13.14 Cr 0.00 Cr 0.00 Cr 0.89 Cr 21.6148 Cr
2022-03-31 0.04 Cr 56.45 Cr 28.08 Cr 28.3606 Cr 16.43 Cr 16.39 Cr 17.49 Cr 13.78 Cr 0.67 Cr 0.00 Cr 0.00 Cr 23.6470 Cr
2021-03-31 0.04 Cr 49.88 Cr 23.12 Cr 26.7662 Cr 12.97 Cr 12.94 Cr 11.87 Cr 13.19 Cr 0.47 Cr 0.00 Cr 0.00 Cr 16.2357 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2025-03-31 3.7219 Cr -2.3182 Cr -1.4282 Cr 1.3892 Cr -0.0245 Cr 0.1209 Cr -2.3327 Cr 0.6914 Cr 0.5985 Cr 0.0000 Cr -2.3457 Cr
2024-03-31 0.7924 Cr -1.0086 Cr 0.2833 Cr -0.2255 Cr 0.0670 Cr 0.1454 Cr -1.0179 Cr 0.4724 Cr 0.4568 Cr 0.0000 Cr -2.8584 Cr
2023-03-31 1.6630 Cr -2.2656 Cr 0.6240 Cr 0.8065 Cr 0.0215 Cr 0.0784 Cr -0.8566 Cr 0.9855 Cr -0.1903 Cr 0.0000 Cr -0.6863 Cr
2022-03-31 0.7742 Cr -2.4439 Cr 1.6786 Cr -1.6819 Cr 0.0089 Cr 0.0444 Cr -2.4561 Cr 2.2481 Cr 3.4611 Cr 0.0000 Cr -5.6181 Cr
2021-03-31 0.0000 Cr 0.0000 Cr 2.0736 Cr -3.6740 Cr 0.0234 Cr 0.0355 Cr -3.6740 Cr 4.2920 Cr 3.4049 Cr 0.0000 Cr 4.5594 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2025-09-30 10.28 Cr 7.72 Cr 2.56 Cr 0.2489 0.76 Cr 0.19 Cr 0.19 1.10 Cr 0.0187
2025-06-30 13.61 Cr 11.42 Cr 2.19 Cr 0.1608 0.65 Cr 0.12 Cr 0.12 1.02 Cr 0.0087
2025-03-31 10.39 Cr 7.91 Cr 2.49 Cr 0.2392 0.65 Cr 0.04 Cr 0.04 1.05 Cr 0.0037
2024-12-31 10.80 Cr 8.15 Cr 2.65 Cr 0.2455 1.02 Cr 0.23 Cr 0.23 1.39 Cr 0.0210
2024-09-30 12.36 Cr 10.15 Cr 2.21 Cr 0.1785 0.53 Cr 0.04 Cr 0.04 0.88 Cr 0.0035

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2025-09-30 0.17 Cr 0.32 Cr 0.49 Cr 17.24 Cr 25.68 Cr 45.96 Cr 12.92 Cr 68.61 Cr 34.19 Cr
2025-06-30 0.00 Cr 0.00 Cr 0.23 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -34.11 Cr
2025-03-31 0.12 Cr 0.23 Cr 0.35 Cr 13.60 Cr 25.27 Cr 40.76 Cr 13.57 Cr 65.14 Cr 31.03 Cr
2024-12-31 0.00 Cr 0.00 Cr 0.05 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr -33.88 Cr
2024-09-30 0.02 Cr 0.28 Cr 0.30 Cr 32.98 Cr 24.36 Cr 59.56 Cr 12.19 Cr 73.26 Cr 39.38 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2025-06-30 0.12 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2025-03-31 0.04 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-12-31 0.23 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-09-30 0.04 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2024-06-30 0.03 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹832.50 ₹99,706,606,920.00 ₹80,828.00

Key Executives

Production Manager (Syrups Division)
Rameswar Reddy

Gender: Not Specified

Year Born: 1968

Chief Financial Officer & Whole-Time Director
Seelam Koni Reddy

Gender: male

Year Born: 1989

Company Secretary & Compliance Officer
Namratha Nagla

Gender: female

Year Born:

QC Manager
Ramachandrudu

Gender: Not Specified

Year Born: 1969

Whole-Time Director
Seelam Manoj Kumar Reddy

Gender: male

Year Born: 1990

Chairman of the Board & MD
Seelam Nagi Reddy

Gender: male

Year Born: 1969

Assistant Manager- Production
K. Krishna Prasad

Gender: Not Specified

Year Born: 1970

Production Manager - Tablets Division
V. Phani Sekhar

Gender: Not Specified

Year Born: 1968

FAQs about Concord Drugs Limited

Who is the CEO of the company?

The CEO is Seelam Nagi Reddy.

What is the current market price of the stock?

The current price is ₹84.55.

What is the 52-week price range?

The range is ₹26.1-92.52.

What is the market capitalization of the company?

The market capitalization is ₹84.13 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 148.72.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Concord Drugs Limited (ISIN: INE858L01010) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹84.13 crores and an average daily volume of 10,178 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.